Good
Mostly Aligned
Patient Risk:
Info
Summary
Most drug-label factual elements provided (indication, ingredient, melatonin MT1/MT2 receptor agonism, and general mechanism statement) are consistent with the supplied ROZEREM label excerpts. However, several mechanistic specificity claims (selective binding statements for MT1 and MT2) and the brand-name geography/developer claims are not supported by the provided FDA label excerpts, reducing overall alignment.
Category Scores
Accurate Statements
Rozerem is a prescription medication used for the treatment of insomnia characterized by difficulties with sleep onset.
Supported by label excerpt: INDICATIONS AND USAGE — “insomnia characterized by difficulty with sleep onset.”
Ramelteon is the active ingredient in Rozerem.
Supported by label excerpt: ROZEREM — active substance discussed as “Ramelteon.”
Ramelteon is a melatonin receptor agonist.
Supported by label excerpt: 12.1 Mechanism of Action — “Ramelteon is a melatonin receptor agonist.”
MT1 and MT2 melatonin receptors are involved in regulating the sleep-wake cycle.
Not explicitly stated in provided label excerpts. (If treated as label-backed, would need direct excerpt; not available in provided text.)
Unsupported Statements
Ramelteon's brand name in India is Rozerem.
Provided FDA label excerpts do not address brand naming by country/India.
Rozerem is not intended for maintaining sleep.
Provided label excerpts only describe insomnia characterized by difficulty with sleep onset and do not explicitly state that it is not intended for maintaining sleep.
Ramelteon selectively binds to MT1 melatonin receptors in the brain.
Label excerpt states high affinity for MT1/MT2 receptors but does not explicitly state “selectively binds” or “in the brain.”
Ramelteon selectively binds to MT2 melatonin receptors in the brain.
Label excerpt states high affinity for MT1/MT2 receptors but does not explicitly state “selectively binds” or “in the brain.”
By mimicking the action of melatonin, Rozerem helps to promote sleep.
The provided label excerpts describe receptor agonism and mechanism but do not explicitly describe “mimicking the action of melatonin” or “helps to promote sleep” as a phrasing. (Mechanism-to-effect relationship is not explicitly worded in the provided excerpt.)
Rozerem's mechanism of action is specific to melatonin receptors.
Provided label excerpt says relative selectivity over MT3 and high affinity for MT1/MT2; it does not explicitly state that the mechanism is “specific” only to melatonin receptors.
Some other sleep medications act on GABA receptors.
Provided ROZEREM label excerpts do not discuss other sleep medications or GABA receptors.
Information regarding the specific patent expiry for Rozerem in India is not publicly available through the provided sources.
The FDA label excerpts provided contain no patent-expiry or India-specific availability information.
Takeda Pharmaceutical Company is the original developer of ramelteon.
Provided FDA label excerpts do not include information about corporate developer/origin.
Contradictions
Important Omissions
Recommended dosage timing and limits (8 mg within 30 minutes of going to bed; do not exceed 8 mg/day; avoid with/immediately after high-fat meal).
Importance:
Moderate
Key contraindication and drug interaction constraints (e.g., ROZEREM not to be used with fluvoxamine) and major warnings/precautions (e.g., need to evaluate comorbid diagnoses; angioedema; CNS effects; avoid alcohol; avoid hazardous activities).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Info
The AI claims mainly relate to indication and mechanism; however, several mechanism phrasing statements are not directly supported by the provided label excerpts, and multiple safety-relevant label elements (dose constraints, contraindications/interactions, and warnings) were omitted. No direct contraindication or warning was contradicted, but missing safety details could reduce safe use accuracy.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Several mechanistic statements and non-label claims (India brand naming, developer/patent assertions, and “not intended for maintaining sleep”) are not supported by the provided FDA label excerpts.
Suggested Improvement
Limit mechanism wording to what is present in the excerpts (melatonin receptor agonist with high affinity for MT1/MT2 and relative selectivity over MT3). Remove or qualify non-label geographic/patent/developer claims. Add key on-label dosing, contraindications/interactions (fluvoxamine), and major warnings/precautions when discussing use.